🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Indraprastha Medical Corporation Limited INDRAMEDCO NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.apollohospitals.com/delhi/
Company Profile ↓
₹380.10
-21.70% 1Y
Mkt Cap₹3,484.49 Cr
P/E18.98
P/B4.69
Div. Yield1.18%
52W High₹622.80
52W Low₹349.50
Book Value₹80.76
EPS (TTM)₹20.03

Company Overview

Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 24.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 30.7%.

Consistent Profit Growth

Net profit has compounded at 28.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 19.0, below the sector median of 40.0.

Healthy Margins

Operating margin of 15.1% supports profitability.

Recent Developments

  • Mar 2026 Revenue of ₹1,482.51 Cr (+9.3% YoY); net profit ₹183.62 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +9.3%, earnings +14.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.7%, profit CAGR 28.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.66%
1 Year:9.30%

Compounded Profit Growth

5 Years:28.69%
1 Year:14.06%

Stock Price Performance

1 Year:-21.70%
6 Months:-7.89%
3 Months:-11.00%
1 Month:-0.55%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 11% of range
₹349.50 ₹622.80
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)47.80 · Neutral
Price Performance
1M-0.55%
3M-11.00%
6M-7.89%
1Y-21.70%
Valuation vs Sector

P/E of 18.98 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 24.8%.
  • Healthy ROCE of 30.7%.
  • Compounding revenue at 11.7% over 5 years.
  • Profit CAGR of 28.7% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 39.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
18.98
Industry PE
39.97
Forward P/E
15.45
PEG Ratio
-
Book Value
₹80.76
Price to Book
4.69
P/S
2.34
EV/EBITDA
12.16
Dividend Yield
1.18%

Growth (CAGR)

Revenue 5Y
11.66%
Profit 5Y
28.69%
Revenue (YoY)
9.30%
Earnings (YoY)
14.06%

Profitability & Returns

ROCE
30.67%
ROE
24.80%
ROA
18.52%
Profit Margin
12.39%
Op Margin
15.06%
Gross Margin
37.04%
EPS (Latest Qtr)
₹4.55
EPS (TTM)
₹20.03

Balance Sheet & Liquidity

Debt/Equity
4.98
Quick Ratio
2.41
Current Ratio
2.46
Debt
₹36.86 Cr
Total Assets
₹991.36 Cr
Current Assets
₹416.59 Cr
Working Capital
₹247.04 Cr

Ownership

Promoter Holding
55.39%
Chg in Prom Hold
-
FII / Inst Holding
0.62%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
₹3,484.49 Cr
Total Revenue (TTM)
₹1,482.51 Cr
EBITDA
₹295.67 Cr
Free Cash Flow
₹107.79 Cr
Operating Cash Flow
₹167.44 Cr
Shares Outstanding
₹9.17 Cr
Gross Margin
37.04%
Payout Ratio
22.47%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INDRAMEDCO Indraprastha Medical Corporation Limited NSEPHARMA 380.10 18.98 ₹3,484.49 Cr 1.18% 30.67% 24.80% 11.66% 28.69%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 324.93 Cr333.75 Cr365.06 Cr371.61 Cr364.81 Cr
Cost of Revenue 214.40 Cr213.15 Cr225.63 Cr234.10 Cr235.07 Cr
Gross Profit 110.53 Cr120.60 Cr139.43 Cr137.51 Cr129.74 Cr
Operating Expenses 69.55 Cr70.19 Cr76.46 Cr86.81 Cr80.57 Cr
Operating Income 40.98 Cr50.41 Cr62.97 Cr50.70 Cr49.17 Cr
EBITDA 57.32 Cr67.67 Cr80.05 Cr69.10 Cr67.84 Cr
Interest Expense 1.58 Cr1.49 Cr1.56 Cr1.46 Cr1.49 Cr
Pretax Income 44.53 Cr55.27 Cr68.31 Cr56.39 Cr55.01 Cr
Tax Provision 11.72 Cr14.26 Cr16.85 Cr15.39 Cr13.31 Cr
Net Income 32.81 Cr41.01 Cr51.46 Cr41.00 Cr41.70 Cr
Diluted EPS 3.584.475.614.474.55

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -1,064.95 Cr1,204.06 Cr1,356.36 Cr1,482.51 Cr
Cost of Revenue -720.30 Cr780.96 Cr862.74 Cr933.33 Cr
Gross Profit -344.65 Cr423.10 Cr493.62 Cr549.18 Cr
Operating Expenses -232.35 Cr259.02 Cr293.68 Cr325.89 Cr
Operating Income -112.30 Cr164.08 Cr199.94 Cr223.29 Cr
EBITDA -156.91 Cr207.25 Cr266.92 Cr295.67 Cr
Interest Expense -46.00 L1.06 Cr6.27 Cr6.02 Cr
Pretax Income -117.18 Cr166.11 Cr216.32 Cr246.02 Cr
Tax Provision -31.03 Cr42.15 Cr55.33 Cr62.40 Cr
Net Income -86.15 Cr123.96 Cr160.99 Cr183.62 Cr
Diluted EPS -9.4013.5217.5620.03

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -555.14 Cr723.24 Cr851.62 Cr991.36 Cr
Current Assets -223.08 Cr307.98 Cr431.13 Cr416.59 Cr
Cash & Equivalents -52.26 Cr61.60 Cr61.48 Cr4.93 Cr
Inventory -8.45 Cr7.53 Cr6.99 Cr7.86 Cr
Receivables -68.24 Cr58.40 Cr75.45 Cr112.16 Cr
Total Liabilities -175.69 Cr245.48 Cr254.94 Cr250.99 Cr
Current Liabilities -129.63 Cr165.42 Cr178.71 Cr169.55 Cr
Long Term Debt -----
Total Debt -2.48 Cr33.95 Cr32.76 Cr36.86 Cr
Total Equity -379.45 Cr477.76 Cr596.68 Cr740.37 Cr
Shares Outstanding -9.17 Cr9.17 Cr9.17 Cr9.17 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -144.47 Cr200.15 Cr156.75 Cr167.44 Cr
Investing Cash Flow --107.91 Cr-158.43 Cr-110.99 Cr-177.61 Cr
Financing Cash Flow --26.04 Cr-32.38 Cr-45.88 Cr-46.38 Cr
Capital Expenditure --44.58 Cr-69.39 Cr-36.33 Cr-59.65 Cr
Free Cash Flow -99.89 Cr130.76 Cr120.42 Cr107.79 Cr
Net Change in Cash -10.52 Cr9.34 Cr-12.00 L-56.55 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -32.4%35.1%36.4%37.0%
Operating Margin % -10.5%13.6%14.7%15.1%
Net Margin % -8.1%10.3%11.9%12.4%
ROE % -22.7%25.9%27.0%24.8%
ROCE % -26.4%29.4%29.7%27.2%

Shareholding Pattern

Insiders
55.39%
Institutions
0.62%
Public Float
1.39%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INDRAMEDCO

Google News Sat, 24 Jan 2026

Indraprastha Medical Corporation Limited's (NSE:INDRAMEDCO) stock price dropped 10% last week; individual investors would not be happy - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPbU1aa1pUenRWTTY1N2V4N1hoMTZ5UF9sYnpsMkU4TUdNc0xhV1hXWG92M2prSkU5MG1BeGZobzllMVRKYVhwTXJvNmpwTW9MVHJpa2oxYmFjRW5TZkJrTE13dG5wZ0gtSjRzYWlZVTdubWxDaFhvUHVZanZaSFBZUmxiWGtKcFdQSlQtTE…

Google News Wed, 20 May 2026

Solid Earnings May Not Tell The Whole Story For Indraprastha Medical (NSE:INDRAMEDCO) - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPUWx4QlpHWUZmcnNGZENFUy14QXAwV0x2Q09hOUozc2oxU2c4aTY2UXp4aE9WQlNMcVVUOWZIanhNNmVrWU1PaFU3Tld5Ylg0WGt1MXU2aVdXYkI1VWkwMS00QU5mbTdpa3NPdVJoWFltcXRaMFlTY2d2QUZjd3RLRzhnQzFybEt3NUp5Vn…

Google News Sat, 03 Jan 2026

Indraprastha Medical Corporation Ltd. Share Price Live Today - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNVl96NnNtMHhPVTU2YlFiY1ZWS044aHVWaGxCbnJhMFhRVEdQWGdFaWxhUmEwNG0zWldyeTlSbjE1eHZpNVREaFJCdFR5SEVRc1Y4elVlNUVCeUhEMGUtOUJKUEtSRl9SUEZ4c0V1RkRjX2xIUEJocmg0X3UzRGl5bUJfYmJSZi1ZcTdtWj…

Google News Wed, 05 Nov 2025

Indraprastha Medical Corporation Limited's (NSE:INDRAMEDCO) 31% Share Price Surge Not Quite Adding Up - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOdENxUDhOY3Q2ZUNITG44Q0JLRENRMmdlaUVTTFJBdXg2dHRZOHZ1LWY5SkVUX3FBNF9HbUVnWnBuNUd0aUtKMXZjSl9hTl9DQWk4SkpxbXMwODFMVlFpUkxSVWRrQUFKeFhPRjVINW5McExDaTEwRFpEaWtOZ3l4VmRHaGtwSEM2WE9wWl…

Google News ue, 07 Oct 2025

Indraprastha Medical spurts 20% on heavy volumes; stock hits record high - Business Standard

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPQzlyYW01d1NfanJpNEpyU1hHaGphalhJUXBFQUxUaWlnVDRQQlFqWWo3OENtdEw1cW84VHJpeEF1b2ZYNmNPbzQ2UUxXYzdjbUQ5UUlkenkzNE50bWU0SUJUYWs4ZWJ3ZjdIdWVBNW1UZ2xIU21YTk82NXM5RXNPWDlXN1FTU2FZT21NaH…

Google News ue, 12 May 2026

Indraprastha Medical Corporation Limited Announces Board Meeting for Q4 FY26 Results on May 12, 2026 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOS2E4WWNPd0swVFFEbTQwTWJpQlJSRktIOHVxT2pLdWozYXNZQU5ISU9iU3U0TzNhZmJCY0JnRElVTUVRQ183dGJHLWR4Q1h3WlFwVzlpYmp0aGluLS1IR2dmVUJJVjlXMXBnVFFRa1Jvb3BZNjU4QzRsODJmRFgwRTZSdG9ZLTJfWmN6OT…

INDRAMEDCO — Frequently Asked Questions

What is the current share price of Indraprastha Medical Corporation Limited (INDRAMEDCO)?

As of 2026-07-15 09:52 IST, Indraprastha Medical Corporation Limited (INDRAMEDCO) trades at ₹380.10 on NSE. Its 52-week range is ₹349.50 to ₹622.80.

What is the market capitalisation of INDRAMEDCO?

Indraprastha Medical Corporation Limited (INDRAMEDCO) has a market capitalisation of ₹3,484.49 Cr on NSE.

What is the P/E ratio of INDRAMEDCO?

INDRAMEDCO trades at a trailing price-to-earnings (P/E) ratio of 18.98. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.69.

Does INDRAMEDCO pay a dividend?

Indraprastha Medical Corporation Limited (INDRAMEDCO) currently offers a dividend yield of 1.18%.

What is the return on equity (ROE) of INDRAMEDCO?

INDRAMEDCO has a return on equity (ROE) of 24.80%. Its return on capital employed (ROCE) is 30.67%.

Is INDRAMEDCO a good stock to buy?

This page provides a data-driven analysis of Indraprastha Medical Corporation Limited (INDRAMEDCO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space